Summary:
ModernaTX, Inc. / “A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants.
Qualified Participants Must:
• Female Participants 18 to 40 Years of Age
Qualified Participants May Receive:
Compensation up to $1900 for 14 visits over 2.5 years.